A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Bipolar disorders; Obesity
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 07 Aug 2018 Planned primary completion date changed from 1 May 2019 to 1 May 2020.